Skip to main content
Figure 2 | BMC Neurology

Figure 2

From: Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model

Figure 2

Full-length, transgene-derived amyloid precursor protein (APP) levels in brain homogenates following NMN treatment. (A) Representative Western blots of homogenates isolated from the brains of AD-Tg and non-transgenic (NTG) mice (3 months) probed with 6E10 antibody. (B) Transgene-derived full-length APP (~106kD) is observed in AD-Tg mice with negligible levels in the NTG mice. Full-length APP levels (ratio of APP:β-Actin) are significantly decreased in NMN-treated transgenic (AD-Tg NMN) mice compared to AD-Tg vehicle-treated. Data are presented as the average full-length APP ± SE. N = 6 separate animals per group. *p < 0.05.

Back to article page